• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Patients with Hematologic Cancers Have Lower Rates of Alloimmunization with RhD

February 22, 2017

Over 20% of RhD-negative non-oncology patients exposed to RhD-positive red blood cells (RBCs) become alloimmunized to the RhD antigen. In oncology patients, however, the rate of alloimmunization is much lower because cancer patients are often immunosuppressed. Since the availability of RhD-negative RBCs is limited, researchers retrospectively investigated 4295 transfusions of RhD-positive RBCs that occurred in 545 Rh-negative oncology patients over four years. The overall incidence of RhD sensitization was 14% (76/545) as measured at least 28 days after the first transfusion. Independent of age, race, and the number of RBC units transfused, the rate of alloimmunization was higher in oncology patients with solid cancers (22.6%; p=0.007) or myelodysplastic syndrome (23.3%; p=0.03) compared to those with other hematologic syndromes (6.6%). A better understanding of RhD alloimmunization is needed to help develop strategies to better utilize RhD-negative RBCs.

Reference:

1.  Arora K, Kelley J, Sui D, Ning J, Martinez F, Lichtiger B, Tholpady A. Cancer type predicts alloimmunization following RhD-incompatible RBC transfusions. Transfusion 2017.

 

Filed Under

  • Adverse Events (non-infectious)
  • News
  • RBC Transfusion

Recommended

  • Blood Transfusions Reduce Mortality in Patients with Sickle Cell Anemia

  • FDA Issues Emergency Use Authorization for SARS-CoV-2 Monoclonal Antibody Therapy

  • High-throughput Blood Antigen Array Genotyping for Blood Donors

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

  • Prothrombin Complex Concentrate Is Safe and Effective for Cardiac Surgery Patients with Coagulopathic Bleeding

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley